Many patients reach their goal weight by month 4-6 and transition to a maintenance dose that preserves their results long-term
But I think, at the same time just as we have very good science [when it comes to] developing drugs we also need to have very good science [as we try] to understand why we have this obesity epidemic
Observational studies of patients on GLP-1 medications post-cholecystectomy show that nausea, constipation, and diarrhea occur at similar or sometimes slightly lower rates compared to gallbladder-intact cohorts
In both *in vitro* models using hepatocyte cell lines (e.g., HepG2) and *in vivo* rodent models fed high-fat or methionine-choline deficient (MCD) diets, this formulation is used to investigate the mechanisms of hepatic steatosis
Current clinical manifestations that may indicate primary CoQ 10 deficiency are: (1) steroid-resistant nephrotic syndrome without mutations in NPHS1 and/or NPHS2 genes particularly when associated with deafness, retinopathy, and other neurological defects
Success in this field, however, requires more than good intentions